Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of SHR3680 with Repaglinide and Bupropion in Prostate Cancer
NCT04664725Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Jun 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rezvilutamide in prostate cancer (PCa), sponsored by Hengrui. Primary endpoints: Peak Plasma Concentration at Day 21 and Area under the plasma concentration versus time curve at Day 21. Status: unknown.
02
Drugs
rezvilutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04664725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04664725.